Alector. has been granted a patent for isolated antibodies that specifically bind to human SIRPß1 polypeptides. These antibodies, which include specific amino acid sequences, are intended for use in preventing, reducing risk, or treating conditions in individuals requiring such interventions. GlobalData’s report on Alector gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Alector, Personalized cancer vaccines was a key innovation area identified from patents. Alector's grant share as of July 2024 was 20%. Grant share is based on the ratio of number of grants to total number of patents.
Antibodies targeting human sirpß1 for therapeutic use
The patent US12060422B2 describes a novel isolated antibody that specifically binds to human SIRPß1, detailing its structure through various heavy and light chain variable regions. The claims outline specific amino acid sequences for hypervariable regions (HVRs) and framework regions (FRs) that contribute to the antibody's binding affinity and specificity. The patent includes multiple claims that specify variations of the antibody, including those with different combinations of HVRs and FRs, as well as the potential for the antibody to be a monoclonal or an antibody fragment. The antibody is characterized by its high affinity for human SIRPß1, with a binding affinity (KD) ranging from 0.1 nM to 50 nM.
Additionally, the patent encompasses methods for producing the antibody, including the use of isolated nucleic acids encoding the antibody, vectors, and host cells for expression. It also outlines potential therapeutic applications, indicating that the antibody may be used in treating cancer and neurodegenerative diseases or disorders. The claims further specify the composition of the antibody in pharmaceutical formulations, emphasizing its potential utility in clinical settings. Overall, the patent presents a comprehensive framework for the development and application of this specific antibody targeting human SIRPß1.
To know more about GlobalData’s detailed insights on Alector, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
